DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
CT-011 is an investigational drug.
There have been 12 clinical trials for CT-011. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Pancreatic Neoplasms, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are CureTech Ltd, National Cancer Institute (NCI), and Augusta University.
Recent Clinical Trials for CT-011
|Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma||CureTech Ltd||Phase 1/Phase 2|
|Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma||Yvonne Efebera||Phase 1/Phase 2|
|Gemcitabine and CT-011 for Resected Pancreatic Cancer||Augusta University||Phase 2|